Eun-Ha Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7871720/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Age-dependent pathogenic characteristics of SARS-CoV-2 infection in ferrets. Nature Communications, 2022, 13, 21.	12.8	31
2	Coinfection with SARS-CoV-2 and Influenza A Virus Increases Disease Severity and Impairs Neutralizing Antibody and CD4 ⁺ T Cell Responses. Journal of Virology, 2022, 96, jvi0187321.	3.4	38
3	Multiple HA substitutions in highly pathogenic avian influenza H5Nx viruses contributed to the change in the NA subtype preference. Virulence, 2022, 13, 990-1004.	4.4	1
4	Pathogenic assessment of avian influenza viruses in migratory birds. Emerging Microbes and Infections, 2021, 10, 565-577.	6.5	7
5	Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission. Emerging Microbes and Infections, 2021, 10, 152-160.	6.5	54
6	A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nature Communications, 2021, 12, 288.	12.8	224
7	Molecular Signatures of Inflammatory Profile and B-Cell Function in Patients with Severe Fever with Thrombocytopenia Syndrome. MBio, 2021, 12, .	4.1	25
8	Differences in seroprevalence between epicenter and non-epicenter areas of the COVID-19 outbreak in South Korea. Journal of Microbiology, 2021, 59, 530-533.	2.8	2
9	Single-cell transcriptome of bronchoalveolar lavage fluid reveals sequential change of macrophages during SARS-CoV-2 infection in ferrets. Nature Communications, 2021, 12, 4567.	12.8	43
10	Antiviral effects of human placenta hydrolysate (Laennec®) against SARS-CoV-2 in vitro and in the ferret model. Journal of Microbiology, 2021, 59, 1056-1062.	2.8	7
11	Development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) thermal inactivation method with preservation of diagnostic sensitivity. Journal of Microbiology, 2020, 58, 886-891.	2.8	28
12	Viable SARS-CoV-2 in various specimens from COVID-19 patients. Clinical Microbiology and Infection, 2020, 26, 1520-1524.	6.0	180
13	Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. Cell Host and Microbe, 2020, 27, 704-709.e2.	11.0	815
14	Genetic and pathogenic diversity of severe fever with thrombocytopenia syndrome virus (SFTSV) in South Korea. JCI Insight, 2020, 5, .	5.0	58
15	Greater Efficacy of Black Ginseng (CJ EnerG) over Red Ginseng against Lethal Influenza A Virus Infection. Nutrients, 2019, 11, 1879.	4.1	18
16	Rapid and simple colorimetric detection of multiple influenza viruses infecting humans using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform. BMC Infectious Diseases, 2019, 19, 676.	2.9	144
17	Shedding and Transmission Modes of Severe Fever With Thrombocytopenia Syndrome Phlebovirus in a Ferret Model. Open Forum Infectious Diseases, 2019, 6, .	0.9	14
18	Seroprevalence of Severe Fever with Thrombocytopenia Syndrome Phlebovirus in Domesticated Deer in South Korea. Virologica Sinica, 2019, 34, 501-507.	3.0	4

Eun-Ha Kim

#	Article	IF	CITATIONS
19	A Novel Neuraminidase-Dependent Hemagglutinin Cleavage Mechanism Enables the Systemic Spread of an H7N6 Avian Influenza Virus. MBio, 2019, 10, .	4.1	10
20	Ferret animal model of severe fever with thrombocytopenia syndrome phlebovirus for human lethal infection and pathogenesis. Nature Microbiology, 2019, 4, 438-446.	13.3	66
21	Preclinical evaluation of the efficacy of an H5N8 vaccine candidate (IDCDC-RG43A) in mouse and ferret models for pandemic preparedness. Vaccine, 2019, 37, 484-493.	3.8	7
22	Comparison of the virulence and transmissibility of canine H3N2 influenza viruses and characterization of their canine adaptation factors. Emerging Microbes and Infections, 2018, 7, 1-14.	6.5	14
23	Comparison of the pathogenic potential of highly pathogenic avian influenza (HPAI) H5N6, and H5N8 viruses isolated in South Korea during the 2016–2017 winter season. Emerging Microbes and Infections, 2018, 7, 1-10.	6.5	32
24	Altered virulence of Highly Pathogenic Avian Influenza (HPAI) H5N8 reassortant viruses in mammalian models. Virulence, 2018, 9, 133-148.	4.4	13
25	Evaluation of two different enzyme-linked immunosorbent assay for severe fever with thrombocytopenia syndrome virus diagnosis. Clinical and Experimental Vaccine Research, 2018, 7, 82.	2.2	3
26	Seroprevalence and genetic characterization of severe fever with thrombocytopenia syndrome virus in domestic goats in South Korea. Ticks and Tick-borne Diseases, 2018, 9, 1202-1206.	2.7	21
27	An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness. Journal of General Virology, 2018, 99, 292-302.	2.9	11
28	Pathogenicity and genetic characterisation of a novel reassortant, highly pathogenic avian influenza (HPAI) H5N6 virus isolated in Korea, 2017. Eurosurveillance, 2018, 23, .	7.0	19
29	Generation of a High-Growth Influenza Vaccine Strain in MDCK Cells for Vaccine Preparedness. Journal of Microbiology and Biotechnology, 2018, 28, 997-1006.	2.1	15
30	Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy. Journal of Virology, 2017, 91, .	3.4	18
31	Genetic and phylogenetic characterizations of a novel genotype of highly pathogenic avian influenza (HPAI) H5N8 viruses in 2016/2017 in South Korea. Infection, Genetics and Evolution, 2017, 53, 56-67.	2.3	23
32	Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses. Journal of Virology, 2017, 91, .	3.4	10
33	Genetic characterisation of novel, highly pathogenic avian influenza (HPAI) H5N6 viruses isolated in birds, South Korea, November 2016. Eurosurveillance, 2017, 22, .	7.0	44
34	Injectable and Pathogenâ€Mimicking Hydrogels for Enhanced Protective Immunity against Emerging and Highly Pathogenic Influenza Virus. Small, 2016, 12, 6279-6288.	10.0	8
35	Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus. Virology, 2016, 498, 36-43.	2.4	16
36	Genetic diversity and pathogenic potential of low pathogenic H7 avian influenza viruses isolated from wild migratory birds in Korea. Infection, Genetics and Evolution, 2016, 45, 268-284.	2.3	10

Eun-Ha Kim

#	Article	IF	CITATIONS
37	Genetic characteristics of highly pathogenic H5N8 avian influenza viruses isolated from migratory wild birds in South Korea during 2014-2015. Archives of Virology, 2016, 161, 2749-2764.	2.1	11
38	Growth and Pathogenic Potential of Naturally Selected Reassortants after Coinfection with Pandemic H1N1 and Highly Pathogenic Avian Influenza H5N1 Viruses. Journal of Virology, 2016, 90, 616-623.	3.4	4
39	Mouse adaptation of influenza B virus increases replication in the upper respiratory tract and results in droplet transmissibility in ferrets. Scientific Reports, 2015, 5, 15940.	3.3	20
40	Evaluation of the zoonotic potential of a novel reassortant H1N2 swine influenza virus with gene constellation derived from multiple viral sources. Infection, Genetics and Evolution, 2015, 34, 378-393.	2.3	11
41	Profiling and Characterization of Influenza Virus N1 Strains Potentially Resistant to Multiple Neuraminidase Inhibitors. Journal of Virology, 2015, 89, 287-299.	3.4	54
42	Assessment of mOMV adjuvant efficacy in the pathogenic H1N1 influenza virus vaccine. Clinical and Experimental Vaccine Research, 2014, 3, 194.	2.2	7
43	Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models. Journal of General Virology, 2014, 95, 793-798.	2.9	15
44	Pathobiological features of a novel, highly pathogenic avian influenza A(H5N8) virus. Emerging Microbes and Infections, 2014, 3, 1-13.	6.5	106
45	Avian-derived NS gene segments alter pathogenicity of the A/Puerto Rico/8/34 virus. Virus Research, 2014, 179, 64-72.	2.2	3
46	Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza a virus in mice. Virology Journal, 2013, 10, 104.	3.4	21
47	Adjuvant efficacy of mOMV against avian influenza virus infection in mice. Journal of Microbiology, 2013, 51, 682-688.	2.8	2
48	Establishment of Vero cell RNA polymerase I-driven reverse genetics for Influenza A virus and its application for pandemic (H1N1) 2009 influenza virus vaccine production. Journal of General Virology, 2013, 94, 1230-1235.	2.9	20
49	Immunomodulaton and attenuation of lethal influenza A virus infection by oral administration with KIOM-C. Antiviral Research, 2013, 98, 386-393.	4.1	9
50	Emergence of Mammalian Species-Infectious and -Pathogenic Avian Influenza H6N5 Virus with No Evidence of Adaptation. Journal of Virology, 2011, 85, 13271-13277.	3.4	31